Although the<unk>  procedure has attained unprecedented levels of protein retention after lipid extraction, the technique still loses an estimated 8% of proteins per instance of detergent electrophoresis. Repeated imaging of a single sample would only amplify this loss, as antibody removal is commonly accomplished via the same detergent process that creates the original sample. However, those calculations appear to lack a consistent method for overall protein loss throughout the experiment. ClearLight Biotechnologies, a company founded by Karl Deisseroth, found that the detergent process originally published for antibody removal was not the ideal approach and have developed a destaining solution that was not as detrimental to the tissue integrity. Other potential disadvantages of the technique are the length of time it takes to create and image a sample (the immunohistochemical staining alone takes up to six weeks to perform), and the fact that the acrylamide used is highly toxic and carcinogenic. Time has often been cited as a limiting factor and disadvantage to using the<unk>  technique; however, several academic and biotech companies (Logos Bioscience, ClearLight Biotechnologies) have continued to develop and optimize<unk>  reagents that significantly truncated the immunostaining time frame reducing the process from six weeks to as quickly as a week depending on sample type. All tissue clearings have their own safety issues. While acrylamide is considered to be toxic and carcinogenic, its components are similar to those found in gels used for western blots.
CLARITY
Component causes
Actifed
Guaranteed issue
Comstock laws
Conflict procedure
Biocybernetics
Circumcision controversies